自免 TCE 风起云涌,中国 Biotech 差异化布局领跑全球

医麦客
01 Jul

2025 年 7 月 1 日医麦客新闻 eMedClub News从肿瘤转向自免蓝海,新一代 TCE 疗法正改写全球医药研发格局,也有望接棒 ADC 成为下一个创新药投资风口。2024 年年末,美国一家成立仅 3 个月的公司 Candid Therapeutics 在同一天内宣布三笔关于 TCE 的合作交易,交易方均是中国企业,总潜在金额超 13.2 亿美元(折合人民币近百亿元)。当然,这并非个例...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10